GlassScriptPhysician profile
Marshall Frances Lauer
NPI 1306800859
$13,859.13
in general payments reported to CMS, 2019-2025
45 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,840 · 2020: $1,036 · 2021: $3,172 · 2022: $1,933 · 2023: $1,627 · 2024: $2,206 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,818 · Education: $59.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,817.58 |
| Education | $59.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,007.38 | 2022-2025 | |
| Biodelivery Sciences International, INC. | $1,899.74 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,894.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,377.41 | 2021-2025 | |
| Novo Nordisk INC | $905.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $674.89 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $619.23 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Allergan, INC. | $503.25 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $482.94 | 2021-2025 | Belbuca, Xtampza |
| Lilly USA, LLC | $444.80 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $304.16 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $275.81 | 2023-2025 | Caplyta |
| Orexo US, INC. | $233.80 | 2019-2024 | Zubsolv |
| Astellas Pharma US INC | $221.96 | 2019-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $210.98 | 2022-2025 | Quviviq, Quviviq |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $200.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.63 | 2019-2023 | Stiolto Respimat, Spiriva Respimat, Combivent Respimat |
| Indivior INC. | $134.38 | 2019-2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $127.28 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $122.71 | 2019 | |
| Alkermes, INC. | $111.61 | 2019-2021 | |
| Boston Scientific Corporation | $107.51 | 2023 | Ranger |
| Merck Sharp & Dohme LLC | $103.57 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $87.09 | 2020-2021 | |
| Protega Pharmaceutials INC | $80.21 | 2024 | Roxybond |
| Braeburn INC. | $65.21 | 2024-2025 | Brixadi |
| Dexcom, INC. | $59.33 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $45.14 | 2023-2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $42.79 | 2022 | |
| Sanofi Pasteur INC. | $41.75 | 2019-2023 | |
| Uswm, LLC | $36.12 | 2021-2022 | |
| Lundbeck LLC | $36.00 | 2025 | Rexulti |
| Amarin Pharma, INC. | $35.94 | 2019-2021 | |
| Glaxosmithkline, LLC. | $32.33 | 2024 | Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $28.01 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $27.03 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.88 | 2025 | |
| Amgen INC. | $16.81 | 2024 | Prolia, Evenity |
| Linus Health, INC. | $15.25 | 2023 | |
| Axsome Therapeutics, INC. | $14.58 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $14.43 | 2022 | |
| Radius Health, INC. | $14.19 | 2023 | |
| Daiichi Sankyo INC. | $13.71 | 2019 | |
| Seqirus USA INC | $12.03 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Lauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.